

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (Currently Amended) An isolated nucleic acid comprising a nucleotide sequence encoding a[[n]] C. albicans polypeptide of SEQ ID NO:17026 ~~selected from the group consisting of SEQ ID NO: 14104—SEQ ID NO: 28206.~~
2. (Original) A recombinant expression vector comprising the nucleic acid of claim 1 operably linked to a transcription regulatory element.
3. (Original) A cell comprising a recombinant expression vector of claim 2.
4. (Currently Amended) A method for producing a[[n]] C. albicans polypeptide comprising culturing a cell of claim 3 under conditions that permit expression of the polypeptide.
5. (Currently Amended) An isolated nucleic acid comprising a nucleotide sequence encoding a[[n]] C. albicans polypeptide or a fragment thereof, wherein said nucleic acid is SEQ ID NO:2923 ~~selected from the group consisting of SEQ ID NO: 1—SEQ ID NO: 14103.~~
6. (Original) A recombinant expression vector comprising the nucleic acid of claim 5 operably linked to a transcription regulatory element.
7. (Original) A cell comprising a recombinant expression vector of claim 6.
8. (Currently Amended) A method for producing a[[n]] C. albicans polypeptide comprising culturing a cell of claim 7 under conditions that permit expression of the polypeptide.

9. (Withdrawn) A probe comprising a nucleotide sequence having at least 8 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 14103.
10. (Withdrawn) An isolated nucleic acid comprising a nucleotide sequence of at least 8 nucleotides in length, wherein the sequence is hybridizable to a nucleic acid having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 - SEQ ID NO: 14103.
11. (Currently Amended) A vaccine composition for prevention or treatment of a *C. albicans* infection comprising an effective amount of a nucleic acid of claim 5 and a pharmaceutically acceptable carrier.
12. (Original) A vaccine composition of claim 11, further comprising an adjuvant.
13. (Original) A vaccine composition of claim 11, further comprising one or more additional active ingredients.
14. (Withdrawn) A method of treating a subject for *C. albicans* infection comprising administering to a subject a vaccine composition of claim 11, 12 or 13, such that treatment of *C. albicans* infection occurs.
15. (Withdrawn) A method of claim 14, wherein the treatment is a prophylactic treatment.
16. (Withdrawn) A method of claim 14, wherein the treatment is a therapeutic treatment.

17. (Withdrawn) A recombinant or substantially pure preparation of an *C. albicans* polypeptide or a fragment thereof, wherein said polypeptide is selected from the group consisting of SEQ ID NO: 14104 - SEQ ID NO: 28206.
18. (Withdrawn) A vaccine composition for prevention or treatment of an *C. albicans* infection comprising an effective amount of an *C. albicans* polypeptide of claim 17 and a pharmaceutically acceptable carrier.
19. (Withdrawn) A vaccine composition of claim 18, further comprising an adjuvant.
20. (Withdrawn) A vaccine composition of claim 18, further comprising one or more additional active ingredients.
21. (Withdrawn) A method of treating a subject for *C. albicans* infection comprising administering to a subject a vaccine composition of claim 18, 19 or 20, such that treatment of *C. albicans* infection occurs.
22. (Withdrawn) A method of claim 21, wherein the treatment is a prophylactic treatment.
23. (Withdrawn) A method of claim 21, wherein the treatment is a therapeutic treatment.
24. (Withdrawn) A method for detecting the presence of a *Candida* nucleic acid in a sample comprising:
  - (a) contacting a sample with a nucleic acid of claim 5 under conditions in which a hybrid can form between the probe and a *Candida* nucleic acid in the sample; and
  - (b) detecting the hybrid formed in step (a), wherein detection of a hybrid indicates the presence of a *Candida* nucleic acid in the sample.

25. (Withdrawn) A computer readable medium having recorded thereon the nucleotide sequences depicted in SEQ ID NO: 1 - SEQ ID NO: 14103 or fragments thereof.
26. (Withdrawn) A computer based system for identifying fragments of the Candida genome of commercial importance comprising the following elements;
  - a) a data storage means comprising the nucleotide sequences SEQ ID NO: 1 - SEQ ID NO: 14103 or fragments thereof,
  - b) a search means for comparing a target sequence to the nucleotide sequences of the data storage means of step (a) to identify homologous sequences, and;
  - c) a retrieval means for obtaining said homologous sequences(s) of step (b).
27. (Withdrawn) A method of identifying commercially important nucleic acid fragments of the Candida genome comprising the step of comparing a database comprising the nucleotide sequences SEQ ID NO: 1 - SEQ ID NO: 14103 or fragments thereof with a target sequence to obtain a nucleic acid molecule comprised of a complementary nucleotide sequence to said target sequence, wherein said target sequence is not randomly selected.
28. (Withdrawn) A method for identifying an expression modulating fragment of the Candida genome comprising the step of comparing a database comprising the nucleotide sequences SEQ ID NO: 1 - SEQ ID NO: 14103 or fragments thereof with a target sequence to obtain a nucleic acid molecule comprised of a complementary nucleotide sequence to said target sequence, wherein said target sequence comprises sequences known to regulate gene expression.